BioSpace News Archive

NanoMosaic, the multiplex and multi-omic quantification company, announced the expanded capabilities and availability of assays optimized on its Tessie™ system for use in gene therapy applications.

Geneos Therapeutics announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, at the 2024 American Association for Cancer Research Annual Meeting.

Tango Therapeutics, Inc. announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March.

Vedanta Biosciences announced that management will host investor meetings at the Leerink Partners 2024 Global Biopharma Conference being held in Miami, FL from Monday, March 11 through Wednesday, March 13, 2024.

Scribe Therapeutics Inc. announced that co-founder and CEO Benjamin Oakes, Ph.D., and CFO David Parrot will participate in the upcoming Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and Wednesday, March 13, 2024 in Miami Beach, FL.

Creative Medical Technology Holdings, Inc. is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration for CELZ-101, ImmCelzTM.

C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.

VedaBio today announced that Frédéric Sweeney, PhD, has been appointed President and Chief Executive Officer. He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio.

Kura Oncology, Inc. today announced dosing of the first patient with KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), in combination with the tyrosine kinase inhibitor (TKI) cabozantinib in the clear cell renal cell carcinoma (ccRCC) cohort of the Phase 1 portion of the FIT-001 trial.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer.